Entera Bio Ltd - Warrants (02/07/2023)
ENTXW
Get informed when a big investor buys or sells
+ FollowMarket Cap$142.45M
Close$
$0.37
30433.3% upside
Current Fair Value
30433.3% upsideUndervalued by 30433.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $142.45 Million |
|---|---|
| Enterprise Value | $131.56 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.25 |
| Beta | 0 |
| Outstanding Shares | 50,451,232 |
Return
| Return on Equity | 219.52% |
|---|---|
| Return on Assets | 81.88% |
| Return on Invested Capital | -18.42% |
Valuation & Multiples
| P/E Ratio | -8.34 |
|---|---|
| PEG | 2.22 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -41.11 |
| Enterprise Value to Net Income | 8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Entera Bio Ltd
17 employees
CEO: Adam Gridley Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challeng...